Leerink Partners analyst Puneet Souda has maintained their bullish stance on BRKR stock, giving a Buy rating on May 8.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Puneet Souda has given his Buy rating due to a combination of factors related to the recent settlement of litigation involving Bruker and Nanostring. The resolution of this legal dispute is seen as a positive development for Bruker, as it removes a significant legal overhang that could have impacted the company’s operations and financials. The settlement, which dismisses all claims with prejudice, suggests that Bruker will not face further legal challenges from this particular case, allowing the company to focus on its core business activities without the distraction of ongoing litigation.
Furthermore, the settlement is expected to reduce potential legal costs for Bruker, which is a favorable outcome for the company’s financial health. The dismissal of claims also indicates a mitigation of risks associated with the litigation, providing a clearer path forward for Bruker’s spatial operations in the U.S. market. Overall, the resolution of these legal issues is likely to enhance investor confidence in Bruker’s future prospects, supporting the Buy rating assigned by Puneet Souda.
In another report released on May 8, J.P. Morgan also maintained a Buy rating on the stock with a $60.00 price target.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BRKR in relation to earlier this year.